6.2.3.1.3. hypofractionation. fractionated rt utilises differences dna repair capacity normal tumour tissue slowly proliferating cells sensitive increased dose per fraction . meta-analysis 25 studies including > 14,000 patients concluded since pca slow proliferation rate, hypofractionated rt could effective conventional fractions 1.8–2 gy . hypofractionation (hfx) added advantage convenient patient lower cost. moderate hfx defined rt 2.5–3.4 gy/fx. several studies report moderate hfx applied various techniques also including ht part [658-665]. sr concluded studies moderate hfx (2.5–3.4 gy/fx) delivered conventional 3d-crt/imrt sufficient follow-up support safety therapy long-term efficacy data still lacking . results confirmed cochrane review moderate hfx clinically localised pca . eleven studies included (n = 8,278) median follow-up 72 months showing little difference pca-specific survival (hr: 1.00). based 4 studies (n = 3,848), hfx probably makes little difference late radiation gu toxicity (rr: 1.05) gi toxicity (rr: 1.1), conclusion based relatively short follow-up, ten 15-year data required confirm findings. moderate hfx done experienced teams using high-quality ebrt using igrt imrt/vmat published phase iii protocols adhered (table 6.1.7). table 6.2.7: major phase iii randomised trials moderate hypofractionation primary treatment study/authornrisk, isup grade, nccnadtrt regimenbed, gymedian fu, mooutcomelee, et al. 2016 550542low risknone70 gy/28 fx73.8 gy/41 fx8069.6705 yr. dfs 86.3%(n.s.)5 yr. dfs 85.3%dearnaley, et al. chhip 2016 1,077/19 fx1,074/20 fx1,065/37 fx15% low 73% intermediate 12% high3-6 mo. ebrt57 gy/19 fx60 gy/20 fx74 gy/37 fx73.377.174625 yr. bcdf 85.9% (19 fx) 90.6% (20 fx) 88.3% (37 fx)de vries, et al., 2020 40339230% isup grade 145% isup grade 2-3,25% isup grade 4-5none64.6 gy/19 fx78 gy/39 fx90.478898-yr. os 80.8% vs. 77.6%(p = 0.17)8 yr. tf 24.4% vs. 26.3%catton, et al. 2017 608intermediate risk53% t1c 46% t2a-cnone60 gy/20 fx77.1725 yr. bcdf arms 85%hr: 0.96 (n.s)5989% isup grade 163% isup grade 228% isup grade 378 gy/39 fx78 adt = androgen deprivation therapy; bcdf = biochemical clinical disease failure; bed = biologically equivalent dose, calculated equivalent 2 gy fractions using α/ss 1.5 gy; dfs = diseasefree survival;ebrt = external beam radiotherapy; fu = follow-up; fx = fractions; hr = hazard ratio; isup = international society urological pathology; mo. = month; n = number patients; nccn = national comprehensive cancer network;n.s. = significant; tf = treatment failure; yr. = year. ultra-hfx defined rt > 3.4 gy per fraction . requires igrt (ideally) stereotactic body rt (sbrt). table 6.1.8 provides overview selected studies investigating role treating predominantly intermediate risk localised disease. short-term biochemical control (5-years) comparable conventional fractionation. however, concerns high-grade gu rectal toxicity full long-term side effects may yet known . hypo-rt-pc randomised trial widmark et al., (n = 1,200), difference failure-free survival seen conventional ultra-hfx acute grade ≥ 2 gu toxicity 23% vs. 28% (p = 0.057), favouring conventional fractionation. significant differences long-term toxicity . sr jackson et al., included 38 studies 6,116 patients received rt < 10 fractions ≥ 5 gy per fraction. five seven-year biochemical recurrence-free survival (brfs) rates 95.3% 93.7%, respectively, estimated late grade ≥ 3 gu gi toxicity rates 2.0% 1.1%, respectively . authors conclude sufficient evidence support sbrt standard treatment option localised pca, even though median follow-up review 39 months included least one trial (hypo-rt-pc) used 3d-crt 80% imrt/vmat remainder ultra-hfx. review sbrt, cushman et al., evaluated 14 trials, including 2,038 patients concluded despite lack long-term follow-up heterogeneity available evidence, prostate sbrt affords appropriate biochemical control high-grade toxicities . intensity-modulated fractionated rt vs. stereotactic body rt pca (pace-b) trial, acute grade ≥ 2 gu gi toxicities differ significantly conventional fractionation ultra- hfx . two years, treatment well tolerated arms differences rtog ≥ grade 2 gu gi toxicities, clinician scoring urinary toxicity using ctcae patient reported expanded prostate cancer index composite (epic)-26 urinary bother scores higher sbrt arm suggesting sbrt may increase moderate severe urinary symptoms post-teatment . adopting planning dose constraints penile bulb might minimise ed, especially younger patients (table 6.1.8) . first results small (n = 30) randomised phase-ii trial intermediate-risk pca ‘ultra-high single dose rt’ (sdrt) 24 gy compared ultra hfx stereotactic body rt regime 5x9 gy, published . table 6.2.8: selected trials ultra-hypofractionation intact localised pca studynmed fu (mo)risk-groupregimen (td/fx)outcomewidmark et al. 2019hypo-rt-pc 1,2006089% intermediate11% high78 gy / 39 fx, 8 wk.42.7 gy / 7 fx, 2.5 wk.no sbrtffs 5 yr.84% armsbrand et al. 2019pace-b 847variable8% low92% intermediate78 gy / 39 fx, 8 wk.36.25 gy / 5 fx, 1-2 wk.sbrtno difference acute toxicitygrade ≥ 2 2-year gi3% vs. 2%, p =nsgrade ≥ 2 2-year gu2% vs. 3%, p =ns ffs = failure-free survival; fu = follow-up; fx = number fractions; gi = gastro-intestinal toxicity; gu = genitourinary toxicity; mo. = months; n = number patients; td = total dose; sbrt = stereotactic body radiotherapy;wk. = weeks; yr. = years; ns=not significant.